Lactobacillus casei
EVIDENCE: WEAKAlso sold as: L. casei, LC16, L. casei Shirota, Lacticaseibacillus casei, Yakult strain
L. casei is a probiotic species with human digestive and immune research. Laboratory work includes activity against vaginal pathogens such as Candida. Direct urinary or bladder benefits are not established by those findings.
Compiled by iSupplementReviews editorial team ·Updated 2026-10-06 · 3 sources
- Type
- Probiotic — digestive and immune species
- Studied dose
- 1–10 billion CFU/day (digestive and immune trials, mostly the Shirota strain)
- Best form
- Named strain (Shirota has the human data); uncharacterized deposit strains carry no evidence
- Our rating
- WEAK — Mostly small, animal, or traditional evidence
What is Lactobacillus casei?
L. casei, now classified as Lacticaseibacillus casei, is an acid-tolerant probiotic species associated with fermented drinks such as Yakult. Its human research mainly concerns digestive and immune outcomes, with more limited laboratory vaginal-pathogen research.
Other names and forms it’s sold as
- L. casei Shirota (LcS): the Yakult strain with the human trials
- LC16, DN-114001 (DanActive) and other commercial strains
- Mostly appears in multi-strain blends
Where does it come from?
Fermented dairy and the human digestive tract: one of the most acid-resistant lactobacilli, which is why it features in products needing shelf-stable organisms.
How does it work in the body?
Immune modulation via the gut (the documented mechanism in LcS trials), lactic-acid production, and competitive exclusion. Lab work shows it inhibits Candida species, including antifungal-resistant isolates. That’s the rationale for its inclusion in vaginal formulas, and it’s a lab finding rather than a clinical result.
What is it claimed to do?
Immune and digestive support (real), vaginal candida protection (laboratory only), and in urinary formulas, microbiome “balance” (undefined).
What does the research show?
| Claim | Evidence | Dose studied | Verdict |
|---|---|---|---|
| Immune / respiratory-infection incidence | Human trials (LcS) | ~10⁹–10¹⁰ CFU/day | Supported, modest |
| Antibiotic-associated diarrhea | Human trials | ~10⁹ CFU/day | Supported |
| Anti-Candida activity | Lab work only | — | Lab finding only |
| UTI / bladder control | None | — | No evidence |
The Candida data — the bridge to vaginal claims
Paniágua et al. (2021, BMC Complement Med Ther), a study the FemiCore page itself cites, found L. casei Shirota inhibited Candida isolates, including antifungal-resistant strains, in lab work. Useful for the hypothesis stack; not a finding about women, bladders, or leaks.
What it does well
LcS has real human evidence for modestly reducing respiratory-infection incidence and antibiotic-associated diarrhea: digestive and immune outcomes. In a urinary formula, that evidence doesn’t travel; the species’ candida-inhibition finding is the only thread connecting it to urogenital claims, and it’s a test-tube thread.
What doesn’t L. casei do?
Nothing measured: no urinary, urgency, leak, or bladder-control outcomes in any human study; no demonstrated vaginal colonization from oral dosing; and it’s a minor species in the vaginal flora whose protective role is assumed from its genus, not demonstrated.
What dose was studied?
| Goal | Dose | Form/route | Duration |
|---|---|---|---|
| Immune outcomes | ~10⁹–10¹⁰ CFU/day (LcS) | oral, fermented milk | weeks–months |
| Antibiotic-associated diarrhea | ~10⁹ CFU/day | oral | duration of antibiotics |
Side effects
Decades-long global consumption record: among the safest organisms sold. Initial gas/bloating is the worst of it.
Drug interactions
- Antibiotics: space dosing or take post-course
- Immunosuppressants: class-level caution for the severely immunocompromised
Who should not take it?
Severely immunocompromised patients; everyone else has a century of safe use behind it.
What the authorities say
GRAS food organism; NCCIH-recognized as safe; EFSA has evaluated various LcS claims (approving none for urogenital outcomes). Institutional status: safe and proven for the gut, silent on the urinary tract.
What to know about Lactobacillus casei
L. casei’s digestive and immune studies do not establish urinary or bladder benefits. Laboratory anti-Candida activity is a different kind of evidence. Identify the strain and count rather than treating its familiar name as proof.
Frequently asked questions about Lactobacillus casei
Does Lactobacillus casei do anything for urinary health?
Not demonstrated. Its evidence base is gastrointestinal and immune; the anti-Candida data behind its inclusion in vaginal formulas is laboratory only. It's a minor, occasional member of vaginal flora, not a core protective species like L. crispatus or L. gasseri.
What is L. casei proven for?
Gut and immune outcomes. The Shirota strain (Yakult) has human trials for reducing respiratory-infection incidence, antibiotic-associated diarrhea, and improving bowel regularity. That's a digestive and immune research record, not a urinary one.
Is L. casei the same as the bacteria in Yakult?
Yes. Yakult's single strain is L. casei Shirota (LcS), one of the most-consumed probiotic strains on earth. Its decades of human use give it a strong safety record, though most efficacy data concerns the gut.
Is L. casei safe?
Yes; among the most-consumed probiotic species globally. The standard class caution applies only to severely immunocompromised patients.
References
- [1]L. casei Shirota inhibits Candida including antifungal-resistant strains — in-vitro study (BMC Complement Med Ther, 2021)
- [2]The role of probiotics in vaginal health — review (Front Cell Infect Microbiol, 2022)
- [3]Fighting polymicrobial biofilms in bacterial vaginosis — review (Microb Biotechnol, 2023)
Products we reviewed containing Lactobacillus casei
Based on recorded labels or seller-described formulas. Inclusion does not establish a match to the strains, preparations or amounts studied here; check each review's disclosure limits.